Unternehmen Merck & Co., Inc. Euronext Paris
Aktien
A0YD8Q
US58933Y1055
MRK
Pharmazeutika
Kurzporträt
- Verkauf von pharmazeutischen Produkten (69,7%): zur Behandlung von Bluthochdruck, Osteoporose, Arteriosklerose, Atemwegserkrankungen, bakteriellen und Pilzerkrankungen, Augenkrankheiten und urologischen Erkrankungen, akuter Migräne, Haarausfall bei Männern usw.;
- Verkauf von Impfstoffen (18%);
- Verkauf von Tierarzneimitteln (9,4%);
- Sonstiges (2,9%).
Der Nettoumsatz verteilt sich geografisch wie folgt: Vereinigte Staaten (45,9%), Europa/Naher Osten/Afrika (24,5%), China (8,8%), Japan (6,1%), Asien/Pazifik (6,1%), Lateinamerika (4,3%) und Sonstige (4,3%).
Mitarbeiterzahl: 71 000
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Pharmaceutical
89,1
%
| 52 005 | 87,7 % | 53 583 | 89,1 % | +3,03 % |
Animal Health
9,4
%
| 5 550 | 9,4 % | 5 625 | 9,4 % | +1,35 % |
Other
1,5
%
| 1 728 | 2,9 % | 907 | 1,5 % | -47,51 % |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
47,4
%
| 27 206 | 45,9 % | 28 480 | 47,4 % | +4,68 % |
Europe, Middle East and Africa
22,0
%
| 14 493 | 24,4 % | 13 254 | 22,0 % | -8,55 % |
China
11,3
%
| 5 191 | 8,8 % | 6 802 | 11,3 % | +31,03 % |
Asia Pacific
5,4
%
| 3 614 | 6,1 % | 3 225 | 5,4 % | -10,76 % |
Japan
5,3
%
| 3 629 | 6,1 % | 3 164 | 5,3 % | -12,81 % |
Latin America
5,1
%
| 2 582 | 4,4 % | 3 086 | 5,1 % | +19,52 % |
Other
3,5
%
| 2 568 | 4,3 % | 2 104 | 3,5 % | -18,07 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 01.04.14 |
Director of Finance/CFO | 55 | 01.01.90 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 01.08.20 |
Joseph Romanelli
IRC | Investor Relations Contact | 50 | 01.01.96 |
Peter Dannenbaum
IRC | Investor Relations Contact | - | 01.07.17 |
Andre Musto
PRN | Corporate Officer/Principal | - | 01.07.14 |
Brooke Hinkson
PRN | Corporate Officer/Principal | - | 01.08.15 |
Carol Bowden
PRN | Corporate Officer/Principal | - | 01.04.14 |
Dalton Smart
AUD | Comptroller/Controller/Auditor | 58 | 01.11.09 |
James Matteucci
PRN | Corporate Officer/Principal | - | 01.01.03 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 27.11.07 |
Pamela Craig
BRD | Director/Board Member | 67 | 01.09.15 |
Inge Thulin
BRD | Director/Board Member | 69 | 01.03.18 |
Patricia Russo
BRD | Director/Board Member | 71 | 01.09.95 |
Director/Board Member | 69 | 26.05.20 | |
Robert Davis
CEO | Chief Executive Officer | 57 | 01.04.14 |
Douglas Baker
BRD | Director/Board Member | 65 | 24.05.22 |
Stephen Mayo
BRD | Director/Board Member | 62 | 15.03.21 |
Kathy Warden
BRD | Director/Board Member | 52 | 16.03.20 |
Director/Board Member | 71 | 16.03.20 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 3 577 208 962 | 2 531 418 332 ( 70,77 %) | 1 044 402 655 ( 29,20 %) | 70,77 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
13 443 693 | 10,62% | 289 287 301 $ | |
1 739 768 | 5,17% | 21 503 532 $ | |
XILIO THERAPEUTICS, INC. 4,02% | 1 483 414 | 4,02% | 1 498 248 $ |
EVAXION BIOTECH A/S 12,13% | 2 297 884 | 12,13% | 946 728 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
MSD Regional Business Support Center GmbH
MSD Regional Business Support Center GmbH Miscellaneous Commercial ServicesCommercial Services Part of Merck & Co., Inc., MSD Regional Business Support Center GmbH is a German company that provides management consulting services. The company is based in Munich, Germany. Jutta König has been the CEO of the company since 2021. |
Miscellaneous Commercial Services
|
Merck Holdings, Inc.
| |
MSD International GmbH (Switzerland)
MSD International GmbH (Switzerland) Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD International GmbH (Switzerland) is a Swiss company that discovers, develops and markets human and animal health products. The company is located in Switzerland. |
Pharmaceuticals: Major
|
Schering Plough International Finance Co. BV
| |
MSD Human Health Holding BV
MSD Human Health Holding BV Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., MSD Human Health Holding BV discovers, develops and markets human and animal health products. The company is based in Oss, Netherlands. |
Pharmaceuticals: Major
|
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme LLC is a pharmaceutical company. The company is based in Kenilworth, NJ. |
Pharmaceuticals: Major
|
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. |
Pharmaceuticals: Major
|
Essex Chemie AG
| |
Merck Sharp & Dohme BV
Merck Sharp & Dohme BV Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme BV is a Dutch company that manufactures and distributes pharmaceutical products. The company is based in Haarlem, the Netherlands. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
% 1. Jan. | Kap. | |
---|---|---|
+40,73 % | 734 Mrd. | |
+32,83 % | 591 Mrd. | |
-6,30 % | 350 Mrd. | |
+4,05 % | 276 Mrd. | |
+15,00 % | 238 Mrd. | |
+9,78 % | 206 Mrd. | |
-5,52 % | 204 Mrd. | |
+6,17 % | 161 Mrd. | |
-0,45 % | 160 Mrd. |